Background: Data on the prevalence and disease management of chronic urticaria
| INTRODUC TI ON
Chronic urticaria (CU) is a debilitating disease characterized by itching hives, angioedema, or both for more than 6 weeks 1,2 and has two forms, chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CINDU). 2 CSU has spontaneous appearance of urticaria symptoms (ie, hives, angioedema, or both) due to known or unknown causes. 2 CSU is believed to affect 0.5%-1% of the global population at any given time, and it accounts for approximately two-thirds of all cases of CU. 1 In children, urticaria commonly presents as a single acute episode lasting a few days to weeks, and a small proportion of patients are generally reported to progress to a chronic form of the disease. 3 The underlying causes of CU were reported to be similar in children and adults. Subtle changes in clinical characteristics had been observed between children and adults, for example, shorter time to remission, more frequent association with infection, and less frequent occurrence of angioedema in children. 2, 4, 5 CU and CSU have a greater impact on health-related quality of life (HRQoL) in pediatric patients compared to other chronic diseases of childhood including epilepsy and diabetes. 6 Moreover, these conditions could significantly affect children's learning capacity, with time missed from school and negative impact on work for caregivers and parents. 7 The international EAACI/GA 2 LEN/EDF/WAO guidelines have recommended a stepwise treatment approach for CSU management in pediatric patients similar to adult patients. 2 They recommend second-generation non-sedating H1-antihistamines as the first-line treatment, followed by their weight-adjusted up-dosing if symptoms persist for more than 2 weeks. The use of first-generation sedating H1-antihistamines is particularly discouraged for children, as they are more sensitive to higher doses of sedating H1-antihistamines than adults and consequently are more likely to experience side effects. 8 In refractory patients, the current guidelines 2 recommend the use of omalizumab, leukotriene receptor antagonists (LTRAs), or ciclosporin as an add-on therapy to H1-antihistamines. Short-course systemic corticosteroids can be administered during acute exacerbations.
While there is increasing information about the epidemiology, clinical characteristics, and treatment of CU and CSU in adults, there is little published information about these conditions in the pediatric population. 4, [9] [10] [11] Very few studies have reported the prevalence of CU and CSU in pediatric patients. [12] [13] [14] Moreover, these studies were small in size and had limited information regarding geographic variations in prevalence of CU and CSU in the pediatric population.
The objectives of this study were to identify one-year diagnosed prevalence of CU and CSU, as well as, to assess disease characteristics and treatment patterns of CSU in pediatric patients in 5
European countries (United Kingdom (UK), Germany, France, Italy, and Spain).
| ME THODS

| Study design
An online survey (screening and main questionnaire) was conducted during September and October 2015 with physicians recruited from large, representative, national panels in UK, Germany, France, Italy, and Spain ( Figure 1 ).
| Respondent selection
General practitioners, dermatologists/allergists, and pediatricians with 2-30 years of medical practice from primary, secondary, and tertiary healthcare settings were considered eligible and asked to answer the screener questionnaire and were randomly selected to take part in the survey. For the main questionnaire, physicians who treated at least 5 pediatric patients with any condition and at least 1 pediatric patient with CU and CSU in the calendar year 2014 were included. For each country, the total sample (screen out and completes) is representative of the target physician population in that country with respect to geographic region distribution and medical specialty as per national statistics. 
| Screening and main questionnaire
Both questionnaires (see supporting information) referred to a period of 12 months counting for the calendar year 2014. The screening questionnaire contained questions related to the total patients' caseload and the number of pediatric patients seen for any condition and specifically for CU and CSU ( Figure 1 ). In the main questionnaire, the questions focused on CSU disease characteristics including the presence of angioedema, treatment patterns, and physician-assessed response to treatments ( Figure 1 ). Inadequately controlled patients were defined as those who, despite the prescribed treatment, were still symptomatic, presenting hives, itch, and/or angioedema, and required a change in the treatment.
| Outcomes
Three main outcomes were reported: (i) one-year diagnosed preva- 
| Statistical analysis
The diagnosed prevalence of CU and CSU in 2014 in the pediatric population was calculated as per below equations:
In above equations, the nominator value, that is, "pediatric population with CU or CSU during the year of survey," was calculated by summing up the total number of pediatric patients diagnosed, seen, and treated with CU or CSU during the calendar year 2014 by each physician included in the sample. The results from the sample, which include average patient load per physician and the distribution of means, were used to make inferences about the total eligible population of physicians from each country. Statistical calculations combining sample size and variability (standard deviation) were used to generate a confidence interval (95% CI) for all the prevalence estimates.
The total pediatric population in each country within the same time period (denominator value) was obtained from Eurostat.
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The other outcomes, namely treatment patterns, response to treatments, and the presence of angioedema, were reported as proportions. Outcomes were reported for each of the 5 countries and per three different pediatric age groups (0-6 years, 7-11 years, and 12-17 years). 
| RE SULTS
| Prevalence of CU
The estimated number of pediatric patients (aged 0-17 years) suffering from CU in the year 2014 was 825.774 across the 5 countries surveyed. Based on the total pediatric population during this same time period, the prevalence of CU in the pediatric population was estimated to be 1.38% (Table 1 ). The CU prevalence varied from 1.11% to 1.52%, with the highest prevalence observed in France and lowest in Germany ( Table 1 ). The CU prevalence was numerically higher in older age groups (aged 7-11 and 12-17 years) compared to the youngest age group (aged 0-6 years) ( Table 1 ). The differences in prevalence of CU among different countries and age groups were not statistically significant.
| Prevalence of CSU
The estimated number of CSU pediatric patients was 450.123 in five European countries, resulting in prevalence of 0.75% across the five European countries ( Table 2) . Prevalence of CSU ranged from 0.58% to 0.86% with the highest prevalence observed in Italy and lowest in Germany ( Table 2 ). The CSU prevalence was numerically higher in older age groups (aged 7-11 and 12-17 years) compared to the youngest age group (aged 0-6 years) in Germany, France, Italy, and Spain (Table 2 ). These numerical differences among the different countries and age groups were not statistically significant.
| Presence of angioedema in CSU patients
Physicians reported that 5%-14% of their pediatric patients with CSU had angioedema ( Figure 2 ). The estimates of angioedema were numerically higher in the oldest age group (12-17 years) compared to younger age groups (0-6 years and 7-11 years), although the differences were not statistically significant (Figure 2 ).
| Treatment patterns among CSU patients
A large proportion of pediatric CSU patients (>40% in UK, Germany and Italy; >60% in France and Spain) were treated with H1-antihistamines at the approved dose ( Figure 3 ). H1-antihistamines at higher than approved doses were prescribed in 16%-51% of pediatric patients across the countries (Figure 3 ). Other frequently prescribed 
| D ISCUSS I ON
This is the first study that assessed the prevalence of CU and CSU in the pediatric population in five European countries (France, Germany, Italy, Spain, and UK) using a representative online physician survey. The prevalence of CU and CSU in pediatric patients was found to be 1.38% and 0.75%, respectively, across these countries.
These findings suggest that the prevalence of CU and CSU in the pediatric population is similar to that of the adult population. in Korea, which included 4076 children aged 4-13 years from 3 kindergartens and 6 elementary schools, reported a CU prevalence of 1.8% in this population. 16 Although we did not specifically assess the prevalence of chronic inducible urticaria (CINDU) in this study, the assumption that all CU patients who did not have CSU were CINDU patients resulted in a prevalence rate of 0.63. Future studies are required to assess the prevalence of CINDU in the pediatric population.
The presence of angioedema is an important prognostic factor to predict the course of disease in CSU patients. 1 A study by Volonakis et al investigated 226 pediatric CU patients aged 1-14 years for the presence of angioedema and reported that wheals along with angioedema were present in 15% of patients. 17 Our study found that 5%-14% of pediatric CSU patients develop angioedema. In contrast, in adult CSU patients, rates of angioedema are considerably higher, ranging from 33 to 67% in different studies. [18] [19] [20] [21] [22] Interestingly, in adult patients with CSU, a recent real-world study in inadequately controlled CSU patients has found that 32.8%
of patients reported angioedema without having it recorded in the medical forms, indicating a disagreement in reporting of angioedema between physicians and patients. 23 This group of patients reported a similar negative impact of angioedema as the patients with confirmed angioedema. Hence, angioedema might be underestimated in clinical practice. This could also hold true for our study which assessed the presence of angioedema in the pediatric population as
reported by physicians at rates ranging from 5% to 14%. son, we report the data as diagnosed prevalence). This study did not distinguish between sedating and non-sedating H1-antihistamines.
As this study was a physician-based survey, disease characteristics as reported by patients and caregivers were not assessed.
In conclusion, the present study demonstrated that the prevalence of CU and CSU in the pediatric population could be higher than estimated and comparable to that in the adult population.
A large number of pediatric patients are inadequately controlled with currently prescribed treatments, and there is a high unmet need for approved second-line effective treatments of CSU for this population. It is truly worrying that both harmful (oral steroids) and insufficient (topical creams) treatments were frequently used despite better and guideline approved alternatives. Awareness of treatment guidelines among physicians could lead to better adherence to guidelines and thus facilitate improved care for patients.
In the future, more studies are required to further understand the epidemiology, disease burden, and management of CU and CSU in pediatric patients.
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